Thursday, July 29, 2021 1:51:40 PM
Anjalee Khemlani
Anjalee Khemlani·Senior Reporter
Wed, July 28, 2021, 3:45 PM
In this article:
View my watchlists
View my watchlists
Pfizer (PFE) CEO Albert Bourla is betting big on repeating the success of its COVID-19 vaccine with an experimental oral treatment — and he's putting the company's money where its mouth is.
Bourla told Yahoo Finance Wednesday the company is committing $1 billion to develop the oral treatment — a protease inhibitor — which would give the world an easy-to-use, targeted treatment, hopefully by year's end.
The current market for COVID-19 treatments includes monoclonal antibodies and some repurposed drugs, including generics and Gilead Sciences' (GILD) Veklury (formerly Remdesivir) - all of which require being in a hospital or clinic to receive treatment.
Last year, Pfizer jolted the race for a coronavirus shot with its $2 billion commitment, at risk, to develop the COVID-19 vaccine in partnership with BioNTech (BNTX). The approach was different from competitors relying on government funding from what was then Operation Warp Speed, to help with R&D costs.
On Wednesday, the company projected total COVID-19 vaccine revenue could top $33.5 billion for 2021. Of that, Pfizer estimates its cut - after sharing 50% royalties with BioNTech, covering costs and taxes - to be in a range of $8.4 billion to $9.7 billion.
In an earnings call Wednesday, chief scientific officer Mikael Dolsten said Phase 2/3 trials began in July and the company anticipates an emergency use authorization submission in the fourth quarter.
"The goal is to reduce SARS-Cov-2 viral load, thereby hopefully decreasing or preventing symptoms of COVID-19 and minimizing the risk of hospitalization," Dolsten said.
The study focuses on infected patients, and could include anywhere from a five to 10-day treatment course, depending on whether or not the person is exposed to a person with COVID-19, or is just starting to exhibit symptoms of infection.
The push to take on a more nimble, risky pipeline, for the 170-year-old pharma giant, has been a signature of Bourla's since he took the helm of the pharma giant in 2019.
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/18/2024 01:00:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/17/2024 01:13:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 11:04:47 AM
- RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines • PR Newswire (US) • 09/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/05/2024 12:30:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/05/2024 11:05:46 AM
- RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 09/05/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/03/2024 11:03:23 AM
- New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality • PR Newswire (US) • 09/03/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 11:07:16 AM
- RedHill Biopharma Announces First Half 2024 Business Highlights • PR Newswire (US) • 08/29/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 11:02:21 AM
- RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma • PR Newswire (US) • 08/26/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 11:04:32 AM
- Talicia® Launched in the United Arab Emirates • PR Newswire (US) • 08/21/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/20/2024 04:15:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 11:01:08 AM
- RedHill Announces Positive Obesity and Diabetes Results with Opaganib • PR Newswire (US) • 08/19/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 11:13:47 AM
- RedHill Biopharma Announces Plan to Implement ADS Ratio Change • PR Newswire (US) • 08/16/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/13/2024 05:37:51 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:35:44 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/09/2024 11:01:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/07/2024 01:51:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM